Citius Pharmaceuticals, Inc. Proceeds from Commissions Received
Citius Pharmaceuticals, Inc. (CTXR) reported Proceeds from Commissions Received of $6.29 million for the 12-month period ending 2019-09-30, per its 10-K filed 2019-12-16.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromCommissionsReceived · last filed 2019-12-16
- Citius Pharmaceuticals, Inc. proceeds from commissions received for fiscal 2019 was $6.29M, a 29.53% decline from fiscal 2018.
- Citius Pharmaceuticals, Inc. proceeds from commissions received for fiscal 2018 was $8.93M.
| Period end | Proceeds from Commissions Received 12 month |
|---|---|
| 2019-09-30 | $6.29M 10-K · filed 2019-12-16 |
| 2018-09-30 | $8.93M 10-K · filed 2019-12-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |